Advanced search
Publication Cover
Epigenomics Volume 3, 2011 - Issue 1
Submit an article Journal homepage
934
Views
0
CrossRef citations to date
0
Altmetric
Review

DNA Methylation of Tumor Suppressor Mirna Genes: A Lesson from the miR-34 family

Kwan Yeung Wong1 Department of Medicine, Queen Mary Hospital, University of Hong Kong
,
Li Yu2 Department of Hematology, Chinese PLA General Hospital, Beijing100853, China
&
Chor Sang Chim1 Department of Medicine, Queen Mary Hospital, University of Hong KongCorrespondence[email protected]
Pages 83-92 | Published online: 17 Feb 2011

Bibliography

  • Esteller M : Epigenetics in cancer.N. Engl. J. Med.358(11) , 1148–1159 (2008).
  • Laird PW : Cancer epigenetics.Hum. Mol. Genet.14(Suppl. 1) , R65–R76 (2005).
  • Robertson KD : DNA methylation and human disease.Nat. Rev. Genet.6(8) , 597–610 (2005).
  • Herman JG , BaylinSB: Gene silencing in cancer in association with promoter hypermethylation.N. Engl. J. Med.349(21) , 2042–2054 (2003).
  • Jones PA , BaylinSB: The fundamental role of epigenetic events in cancer.Nat. Rev. Genet.3(6) , 415–428 (2002).
  • Saxonov S , BergP, BrutlagDL: A genome-wide analysis of CpG dinucleotides in the human genome distinguishes two distinct classes of promoters.Proc. Natl Acad. Sci. USA103(5) , 1412–1417 (2006).
  • Das PM , SingalR: DNA methylation and cancer.J. Clin. Oncol.22(22) , 4632–4642 (2004).
  • Fazzari MJ , GreallyJM: Epigenomics: Beyond CpG islands.Nat. Rev. Genet.5(6) , 446–455 (2004).
  • Ioshikhes IP , ZhangMQ: Large-scale human promoter mapping using CpG islands.Nat. Genet.26(1) , 61–63 (2000).
  • Kim TH , BarreraLO, ZhengMet al.: A high-resolution map of active promoters in the human genome.Nature436(7052) , 876–880 (2005).
  • Chim CS , LiangR, KwongYL: Hypermethylation of gene promoters in hematological neoplasia.Hematol. Oncol.20(4) , 167–176 (2002).
  • Costello JF , PlassC: Methylation matters.J. Med. Genet.38(5) , 285–303 (2001).
  • Bird A : Molecular biology: DNA methylation de novo.Science286(5448) , 2287–2288 (1999).
  • Singal R , GinderGD: DNA methylation.Blood93(12) , 4059–4070 (1999).
  • Tuck-Muller CM , NarayanA, TsienFet al.: DNA hypomethylation and unusual chromosome instability in cell lines from ICF syndrome patients.Cytogenet. Genome. Res.89(1–2) , 121–128 (2000).
  • Rizwana R , HahnPJ: CpG methylation reduces genomic instability.J. Cell Science112 , 4513–4519 (1999).
  • Knudson AG : Two genetic hits (more or less) to cancer.Nat. Rev. Cancer1(2) , 157–162 (2001).
  • Bartel DP : MicroRNAs: genomics, biogenesis, mechanism, and function.Cell116(2) , 281–297 (2004).
  • Calin GA , CroceCM: MicroRNA signatures in human cancers.Nat. Rev. Cancer6(11) , 857–866 (2006).
  • Esquela-Kerscher A , SlackFJ: Oncomirs – microRNAs with a role in cancer.Nat. Rev. Cancer6(4) , 259–269 (2006).
  • Chen CZ : MicroRNAs as oncogenes and tumor suppressors.N. Engl. J. Med.353(17) , 1768–1771 (2005).
  • Guil S , EstellerM: DNA methylomes, histone codes and miRNAs: tying it all together.Int. J. Biochem. Cell Biol.41(1) , 87–95 (2009).
  • Deng S , CalinGA, CroceCM, CoukosG, ZhangL: Mechanisms of microRNA deregulation in human cancer.Cell Cycle7(17) , 2643–2646 (2008).
  • Lujambio A , EstellerM: CpG island hypermethylation of tumor suppressor microRNAs in human cancer.Cell Cycle6(12) , 1455–1459 (2007).
  • Saito Y , LiangG, EggerGet al.: Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells.Cancer Cell9(6) , 435–443 (2006).
  • Tarasov V , JungP, VerdoodtBet al.: Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest.Cell Cycle6(13) , 1586–1593 (2007).
  • Chang TC , WentzelEA, KentOAet al.: Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis.Mol. Cell26(5) , 745–752 (2007).
  • Raver-Shapira N , MarcianoE, MeiriEet al.: Transcriptional activation of miR-34a contributes to p53-mediated apoptosis.Mol. Cell26(5) , 731–743 (2007).
  • He L , HeX, LimLPet al.: A microRNA component of the p53 tumour suppressor network.Nature447(7148) , 1130–1134 (2007).
  • Bommer GT , GerinI, FengYet al.: p53-mediated activation of miRNA34 candidate tumor-suppressor genes.Curr. Biol.17(15) , 1298–1307 (2007).
  • Corney DC , Flesken-NikitinA, GodwinAK, WangW, NikitinAY: MicroRNA-34b and microRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth.Cancer Res.67(18) , 8433–8438 (2007).
  • Toyota M , SuzukiH, SasakiYet al.: Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer.Cancer Res.68(11) , 4123–4132 (2008).
  • Corney DC , Hwang C-I, Matoso A et al.: Frequent downregulation of miR-34 family in human ovarian cancers. Clin. Cancer Res.16(4) , 1119–1128 (2010).
  • Dalgard C l, Gonzalez M, Deniro JE, O‘Brien JM: Differential microRNA-34a expression and tumor suppressor function in retinoblastoma cells. Invest. Ophthalmol. Vis. Sci.50(10) , 4542–4551 (2009).
  • Duan W , GaoL, WuXet al.: MicroRNA-34a is an important component of prima-1-induced apoptotic network in human lung cancer cells.Int. J. Cancer127(2) , 313–320 (2010).
  • Kumamoto K , SpillareEA, FujitaKet al.: Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate miR-34a, miR-34b, and miR-34c expression, and induce senescence.Cancer Res.68(9) , 3193 (2008).
  • Luan S , SunL, HuangF: MicroRNA-34a: a novel tumor suppressor in p53-mutant glioma cell line u251.Arch. Med. Res.41(2) , 67–74 (2010).
  • Zenz T , HabeS, DenzelTet al.: Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): Dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.Blood114(13) , 2589–2597 (2009).
  • Mraz M , PospisilovaS, MalinovaK, SlapakI, MayerJ: MicroRNAs in chronic lymphocytic leukemia pathogenesis and disease subtypes.Leuk. Lymphoma50(3) , 506–509 (2009).
  • Mraz M , MalinovaK, KotaskovaJet al.: MiR-34a, miR-29c and miR-17–5p are downregulated in CLL patients with TP53 abnormalities.Leukemia23(6) , 1159–1163 (2009).
  • Zenz T , MohrJ, ElderingEet al.: MiR-34a as part of the resistance network in chronic lymphocytic leukemia.Blood113(16) , 3801–3808 (2009).
  • Dijkstra MK , Van Lom K, Tielemans D et al.: 17p13/TP53 deletion in B-CLL patients is associated with microRNA-34a downregulation. Leukemia23(3) , 625–627 (2008).
  • Ji Q , HaoX, MengYet al.: Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres.BMC Cancer8(1) , 266 (2008).
  • Asslaber D , PinonJD, SeyfriedIet al.: MicroRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia.Blood115(21) , 4191–4197 (2010).
  • Wang X , WangHK, McCoyJPet al.: Oncogenic HPV infection interrupts the expression of tumor-suppressive miR-34a through viral oncoprotein E6.RNA15(4) , 637 (2009).
  • Ito T , YagiS, YamakuchiM: MicroRNA-34a regulation of endothelial senescence.Biochem. Biophys. Res. Commun.398(4) , 735–740 (2010).
  • Fujita Y , KojimaK, HamadaNet al.: Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells.Biochem. Biophys. Res. Commun.377(1) , 114–119 (2008).
  • Yamakuchi M , FerlitoM, LowensteinCJ: MiR-34a repression of SIRT1 regulates apoptosis.Proc. Natl Acad. Sci.105(36) , 13421–13426 (2008).
  • Welch C , ChenY, StallingsRL: MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells.Oncogene26(34) , 5017–5022 (2007).
  • Stallings RL , NairP, MarisJMet al.: High-resolution analysis of chromosomal breakpoints and genomic instability identifies PTPRD as a candidate tumor suppressor gene in neuroblastoma.Cancer Res.66(7) , 3673 (2006).
  • Wei JS , SongYK, DurinckSet al.: The MYCN oncogene is a direct target of miR-34a.Oncogene27(39) , 5204–5213 (2008).
  • Cole KA , AttiyehEF, MosseYPet al.: A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene.Mol. Cancer Res.6(5) , 735 (2008).
  • Tazawa H , TsuchiyaN, IzumiyaM, NakagamaH: Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the e2f pathway in human colon cancer cells.Proc. Natl Acad. Sci.104(39) , 15472–15477 (2007).
  • Cheng J , ZhouL, XieQFet al.: The impact of miR-34a on protein output in hepatocellular carcinoma HEPG2 cells.Proteomics10(8) , 1557–1572 (2010).
  • Li N , FuH, TieYet al.: MiR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells.Cancer Lett.275(1) , 44–53 (2009).
  • Pang RT , LeungCO, YeTMet al.: MicroRNA-34a suppresses invasion through downregulation of NOTCH1 and jagged1 in cervical carcinoma and choriocarcinoma cells.Carcinogenesis31(6) , 1037–1044 (2010).
  • Ichimura A , RuikeY, TerasawaK, ShimizuK, TsujimotoG: MicroRNA-34a inhibits cell proliferation by repressing mitogen-activated protein kinase kinase 1 during megakaryocytic differentiation of k562 cells.Mol. Pharmacol.77(6) , 1016–1024 (2010).
  • Navarro F , GutmanD, MeireEet al.: MiR-34a contributes to megakaryocytic differentiation of k562 cells independently of p53.Blood114(10) , 2181–2192 (2009).
  • Hashimi ST , FulcherJA, ChangMH, GovL, WangS, LeeB: MicroRNA profiling identifies miR-34a and miR-21 and their target genes JAG1 and WNT1 in the coordinate regulation of dendritic cell differentiation.Blood114(2) , 404–414 (2009).
  • Witwer KW , SiskJM, GamaL, ClementsJE: MicroRNA regulation of IFN-{β} protein expression: rapid and sensitive modulation of the innate immune response.J. Immunol.184(5) , 2369–2376 (2010).
  • Hermeking H : The miR-34 family in cancer and apoptosis.Cell Death Differ.17(2) , 193–199 (2010).
  • Lodygin D , TarasovV, EpanchintsevAet al.: Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer.Cell Cycle7(16) , 2591–2600 (2008).
  • Gallardo E , NavarroA, VinolasNet al.: MiR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer.Carcinogenesis30(11) , 1903–1909 (2009).
  • Chim CS , WongKY, QiYet al.: Epigenetic inactivation of the miR-34a in hematological malignancies.Carcinogenesis31(4) , 745–750 (2010).
  • Peller S , RotterV: TP53 in hematological cancer: low incidence of mutations with significant clinical relevance.Hum. Mutat.21(3) , 277–284 (2003).
  • Lowe SW , CeperoE, EvanG: Intrinsic tumour suppression.Nature432(7015) , 307–315 (2004).
  • Kozaki K -I, Imoto I, Mogi S, Omura K, Inazawa J: Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res.68(7) , 2094–2105 (2008).
  • Roman-Gomez J , AgirreX, Jimenez-VelascoAet al.: Epigenetic regulation of microRNAs in acute lymphoblastic leukemia.J. Clin. Oncol.27 , 1316–1322 (2009).
  • Meek DW : Tumour suppression by p53: a role for the DNA damage response?Nat. Rev. Cancer9(10) , 714–723 (2009).
  • Soussi T , BeroudC: Assessing TP53 status in human tumours to evaluate clinical outcome.Nat. Rev. Cancer1(3) , 233–239 (2001).
  • Kastan MB , BartekJ: Cell-cycle checkpoints and cancer.Nature432(7015) , 316–323 (2004).
  • Moll UM , PetrenkoO: The MDM2-p53 interaction.Mol. Cancer Res.1(14) , 1001–1008 (2003).
  • Chim CS , FungTK, CheungWC, LiangR, KwongYL: SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the JAK/STAT pathway.Blood103(12) , 4630–4635 (2004).
  • Chim CS , LiangR, TamCYY, KwongYL: Methylation of p15 and p16 genes in acute promyelocytic leukemia: potential diagnostic and prognostic significance.J. Clin. Oncol.19(7) , 2033–2040 (2001).
  • Chim CS , WongASY, KwongYL: Epigenetic dysregulation of the JAK/STAT pathway by frequent aberrant methylation of SHP1 but not SOCS1 in acute leukaemias.Ann. Hematol.83(8) , 527–532 (2004).
  • Chim CS , WongKY, LoongF, LamWW, SrivastavaG: Frequent epigenetic inactivation of Rb1 in addition to p15 and p16 in mantle cell and follicular lymphoma.Hum. Pathol.38(12) , 1849–1857 (2007).
  • Chim CS , WongSY, PangAet al.: Aberrant promoter methylation of the retinoic acid receptor α gene in acute promyelocytic leukemia.Leukemia19(12) , 2241–2246 (2005).
  • Chim CS , KwongYL: Adverse prognostic impact of CDKN2B hyper-methylation in acute promyelocytic leukemia.Leuk. Lymphoma47(5) , 815–825 (2006).
  • Chim CS , LauJS, WongKF, KwongYL: Cdkn2b methylation is an independent poor prognostic factor in newly diagnosed acute promyelocytic leukemia.Leukemia20(1) , 149–151 (2005).
  • Chim CS , LiangR, LeungMH, YipSF, KwongYL: Aberrant gene promoter methylation marking disease progression in multiple myeloma.Leukemia20(6) , 1190–1192 (2006).
  • Chim CS , MaSY, AuWYet al.: Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the international prognostic index.Blood103(1) , 216–221 (2004).
  • Chim CS , TamCYY, LiangR, Kwong Yl: Methylation of p15 and p16 genes in adult acute leukemia. Cancer91(12) , 2222–2229 (2001).
  • Chim CS , WongSY, KwongYL: Aberrant gene promoter methylation in acute promyelocytic leukaemia: profile and prognostic significance.Br. J. Haematol.122(4) , 571–578 (2003).
  • Chim CS , WongASY, KwongYL: Infrequent hypermethylation of cebpa promotor in acute myeloid leukaemia.Br. J. Haematol119(4) , 988–990 (2002).
  • Chim CS , ChanWWL, PangA, KwongYL: Preferential methylation of Wnt inhibitory factor-1 in acute promyelocytic leukemia: an independent poor prognostic factor.Leukemia20(5) , 907–909 (2006).
  • Chim CS , LiangR, FungTK, ChoiCL, KwongYL: Epigenetic dysregulation of the death-associated protein kinase/p14/hdm2/p53/apaf-1 apoptosis pathway in multiple myeloma.J. Clin. Pathol.60(6) , 664–669 (2007).
  • Zenz T , DohnerH, StilgenbauerS: Genetics and risk-stratified approach to therapy in chronic lymphocytic leukemia.Best Pract. Res. Clin. Haematol.20(3) , 439–453 (2007).
  • Meng F , Wehbe-JanekH, HensonR, SmithH, PatelT: Epigenetic regulation of microRNA-370 by interleukin-6 in malignant human cholangiocytes.Oncogene27(3) , 378–386 (2007).
  • Lehmann U , HasemeierB, ChristgenMet al.: Epigenetic inactivation of microRNA gene hsa-miR-9-1 in human breast cancer.J. Path.214(1) , 17–24 (2008).
  • Wilting S , Van Boerdonk R, Henken F et al.: Methylation-mediated silencing and tumour suppressive function of hsa-mir-124 in cervical cancer. Mol. Cancer9(1), 167 (2010).
  • Bandres E , AgirreX, BitarteNet al.: Epigenetic regulation of microRNA expression in colorectal cancer.Int. J. Cancer125(11) , 2737–2743 (2009).
  • Lujambio A , RoperoS, BallestarEet al.: Genetic unmasking of an epigenetically silenced microRNA in human cancer cells.Cancer Res.67(4) , 1424–1429 (2007).
  • Balaguer F , LinkA, LozanoJJet al.: Epigenetic silencing of miR-137 is an early event in colorectal carcinogenesis.Cancer Res.70(16) , 6609–6618 (2010).
  • Grady WM , ParkinRK, MitchellPSet al.: Epigenetic silencing of the intronic microRNA hsa-miR-342 and its host gene EVL in colorectal cancer.Oncogene27(27) , 3880–3888 (2008).
  • Huang Y -W, Liu JC, Deatherage DE et al.: Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer. Cancer Res.69(23) , 9038–9046 (2009).
  • Vrba L , JensenTJ, GarbeJCet al.: Role for DNA methylation in the regulation of miR-200c and miR-141 expression in normal and cancer cells.PLoS ONE5(1) , e8697 (2010).
  • Shen R , PanS, QiS, LinX, ChengS: Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 in gastric cancer.Biochem. Biophys. Res. Commun.394(4) , 1047–1052 (2010).
  • Tsai K -W, Hu L-Y, Wu C-W et al.: Epigenetic regulation of miR-196b expression in gastric cancer. Genes Chromosomes Cancer49(11) , 969–980 (2010).
  • Saito Y , SuzukiH, TsugawaHet al.: Chromatin remodeling at ALU repeats by epigenetic treatment activates silenced microRNA-512-5p with downregulation of Mcl-1 in human gastric cancer cells.Oncogene28(30) , 2738–2744 (2009).
  • Datta J , KutayH, NasserMWet al.: Methylation mediated silencing of microRNA-1 gene and its role in hepatocellular carcinogenesis.Cancer Res.68(13) , 5049–5058 (2008).
  • Lee KH , LottermanC, KarikariCet al.: Epigenetic silencing of microRNA miR-107 regulates cyclin-dependent kinase 6 expression in pancreatic cancer.Pancreatology9(3) , 293–301 (2009).
  • Rauhala HE , JalavaSE, IsotaloJet al.: MiR-193b is an epigenetically regulated putative tumor suppressor in prostate cancer.Int. J. Cancer127(6) , 1363–1372 (2010).
  • Agirre X , Vilas-ZornozaA, Jimenez-VelascoAet al.: Epigenetic silencing of the tumor suppressor microRNA hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia.Cancer Res.69(10) , 4443–4453 (2009).
  • Bueno MJ , Perez De Castro I, Gomez De Cedron M et al.: Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell13(6) , 496–506 (2008).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.